<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939939</url>
  </required_header>
  <id_info>
    <org_study_id>KP MSD 01-08</org_study_id>
    <nct_id>NCT00939939</nct_id>
  </id_info>
  <brief_title>Effect of Sitagliptin on Postprandial Lipoprotein Metabolism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to evaluate whether sitagliptin can affect postprandial lipoprotein
      metabolism in type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment failure
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incremental area under the triglyceride curve (iAUC-TG)</measure>
    <time_frame>10 weeks</time_frame>
    <description>incremental area under the plasma triglyceride concentration curve following a standardized oral fat challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>fasting LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>fasting HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>fasting VLDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>10 weeks</time_frame>
    <description>fasting triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the triglyceride curve (AUC-TG)</measure>
    <time_frame>10 weeks</time_frame>
    <description>area under the plasma triglyceride concentration curve following a standardized oral fat challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the VLDL-triglyceride curve (AUC-VLDL-TG)</measure>
    <time_frame>10 weeks</time_frame>
    <description>area under the plasma VLDL-triglyceride concentration curve following a standardized oral fat challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incremental area under the VLDL-triglyceride curve (iAUC-VLDL-TG)</measure>
    <time_frame>10 weeks</time_frame>
    <description>incremental area under the plasma VLDL-triglyceride concentration curve following a standardized oral fat challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose</measure>
    <time_frame>10 weeks</time_frame>
    <description>fasting glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>10 weeks</time_frame>
    <description>fasting insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin-6</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepirid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin</intervention_name>
    <description>sitagliptin 100 mg/d for 10 weeks</description>
    <arm_group_label>sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>glimepiride 1 mg/d for 10 weeks</description>
    <arm_group_label>glimepirid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  dietary therapy

        Exclusion Criteria:

          -  lipid-lowering therapy

          -  anti-hyperglycemic drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Dept. 2, Grosshadern, University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>June 24, 2011</last_update_submitted>
  <last_update_submitted_qc>June 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Klaus Parhofer</name_title>
    <organization>Med. Dept. 2 University Munich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

